Content in this section will include AAPM advocacy efforts, legislative news, public statements, etc.

FDA MedWatch Safety Alert: Fentanyl Transdermal System by Alvogen - Recall: Due to Product Mislabeling

 Alvogen, Inc. is voluntarily recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level. A small number of cartons labeled 12 mcg/h Fentanyl Transdermal System patches contained 50 mcg/h patches. The 50 mcg/h patches that were included in cartons labeled 12 mcg/h are individually labeled as 50 mcg/h.
Continue reading

Help AAPM and the AMA Opioid Task Force Identify Barriers in Treatment

As one of the organizations in the AMA Opioid Taskforce, AAPM is working with the American Medical Association (AMA) to gather information on barriers to treatment. AAPM and the AMA request 10-15 minutes of your time to ...
Continue reading

CDC Issues Key Clarification on Guideline for Prescribing Opioids for Chronic Pain

The American Society of Clinical Oncology, the American Society of Hematology, and the National Comprehensive Cancer Network® received a letter from the Centers for Disease Control and Prevention (CDC) clarifying the CDC Guideline for Prescribing Opioids for Chronic Pain on prescribing opioids to manage pain from certain conditions. 

Continue reading
Topics:

AAPM Comments on AHRQ Key Questions for Systematic Review on Management of Primary Headaches in Pregnancy

Comments from the American Academy of Pain Medicine The American Academy of Pain Medicine thanks the Agency for the opportunity to comment on The Evidence-based Practice Center Program at the Agency for Healthcare Resear...
Continue reading

FDA Identifies Harm Reported From Sudden Discontinuation of Opioid Pain Medicines

The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide. 

Continue reading
Topics:

HHS Releases Additional $487 Million to States, Territories to Expand Access to Effective Opioid Treatment; 2019 SOR Grants Will Total $1.4 Billion

 

This funding will expand access to treatment that works, especially to medication-assisted treatment (MAT) with appropriate social supports.

Continue reading
Topics:

AHRQ Seeks Input on Headaches in Pregnancy and Acute Pain

The Agency for Healthcare Research and Quality (AHRQ) has posted key questions for the systematic review on Management of Primary Headaches in Pregnancy for comment through April 11, as well as a draft technical brief on...
Continue reading

AAPM Comments on HHS Pain Management Best Practices Inter-Agency Task Force Draft Report

Comments from the American Academy of Pain Medicine (Docket HHS-OS-2018-0027-0001)

The American Academy of Pain Medicine (AAPM) wishes thank the HHS Pain Management Best Practices Inter-Agency Task Force for their dedication and efforts to improve pain care nationally. The document has been thoroughly reviewed by two major committees within AAPM: the Scientific Review and Guidelines Committee and the Behavioral Medicine Committee.

The emphasis on patient-centered and individualized care is appropriate, and special attention to particularly disadvantaged populations and often neglected populations such as children, adolescents, and older adults is appreciated.

A common theme throughout the HHS document is the inclusion of nearly all available options of treatments within a particular category with relative equal emphasis. While this approach provides a comprehensive review of the subjects, it is important to consistently acknowledge the level of evidence supporting any included therapies, as is the standard practice for the publishing of Practice Guidelines.

We provide below several key concerns and recommendations to improve the document and to better align its content with the biospsychosocial model of pain care and current evidence. We urge these recommendations be considered to improve the content of national policy and training needs for providers as well as information available for those who suffer chronic pain.

Continue reading

AAPM Commitment Statement on Countering the U.S. Opioid Epidemic

The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the increasing toll of the harms that can arise from opioid use disorder. As a...
Continue reading
Topics:

State Hits Pause Button on Chronic Pain Proposal

Oregon health officials have delayed consideration of a controversial change under the Oregon Health Plan that could have forced many patients with chronic pain off opioids. 

Continue reading